MNPR
Price
$67.67
Change
+$4.01 (+6.30%)
Updated
Sep 23 closing price
Capitalization
417.52M
ZLAB
Price
$32.07
Change
-$1.08 (-3.26%)
Updated
Sep 23 closing price
Capitalization
3.62B
48 days until earnings call
Interact to see
Advertisement

MNPR vs ZLAB

Header iconMNPR vs ZLAB Comparison
Open Charts MNPR vs ZLABBanner chart's image
Monopar Therapeutics
Price$67.67
Change+$4.01 (+6.30%)
Volume$75.71K
Capitalization417.52M
Zai Lab
Price$32.07
Change-$1.08 (-3.26%)
Volume$589.37K
Capitalization3.62B
MNPR vs ZLAB Comparison Chart in %
Loading...
MNPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNPR vs. ZLAB commentary
Sep 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNPR is a Buy and ZLAB is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 24, 2025
Stock price -- (MNPR: $67.67 vs. ZLAB: $32.07)
Brand notoriety: MNPR and ZLAB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNPR: 193% vs. ZLAB: 75%
Market capitalization -- MNPR: $417.52M vs. ZLAB: $3.62B
MNPR [@Biotechnology] is valued at $417.52M. ZLAB’s [@Biotechnology] market capitalization is $3.62B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNPR’s FA Score shows that 0 FA rating(s) are green whileZLAB’s FA Score has 0 green FA rating(s).

  • MNPR’s FA Score: 0 green, 5 red.
  • ZLAB’s FA Score: 0 green, 5 red.
According to our system of comparison, MNPR is a better buy in the long-term than ZLAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNPR’s TA Score shows that 5 TA indicator(s) are bullish while ZLAB’s TA Score has 5 bullish TA indicator(s).

  • MNPR’s TA Score: 5 bullish, 5 bearish.
  • ZLAB’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ZLAB is a better buy in the short-term than MNPR.

Price Growth

MNPR (@Biotechnology) experienced а +18.72% price change this week, while ZLAB (@Biotechnology) price change was -0.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.75%. For the same industry, the average monthly price growth was +7.78%, and the average quarterly price growth was +47.65%.

Reported Earning Dates

ZLAB is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.75% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLAB($3.62B) has a higher market cap than MNPR($418M). MNPR YTD gains are higher at: 207.591 vs. ZLAB (22.451). MNPR has higher annual earnings (EBITDA): -19.11M vs. ZLAB (-195.33M). ZLAB has more cash in the bank: 732M vs. MNPR (53.3M). MNPR has less debt than ZLAB: MNPR (80.4K) vs ZLAB (191M). ZLAB has higher revenues than MNPR: ZLAB (428M) vs MNPR (0).
MNPRZLABMNPR / ZLAB
Capitalization418M3.62B12%
EBITDA-19.11M-195.33M10%
Gain YTD207.59122.451925%
P/E RatioN/AN/A-
Revenue0428M-
Total Cash53.3M732M7%
Total Debt80.4K191M0%
FUNDAMENTALS RATINGS
ZLAB: Fundamental Ratings
ZLAB
OUTLOOK RATING
1..100
10
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
57
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
MNPRZLAB
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
74%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
78%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 7 days ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 21 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
MNPR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MGRPX79.50N/A
N/A
Morgan Stanley Inst Growth R6
AQGIX13.23-0.04
-0.30%
AQR Global Equity I
TEGYX46.02-0.37
-0.80%
Touchstone Mid Cap Growth Y
NLCAX55.77-0.61
-1.08%
Voya Large-Cap Growth A
ZVNIX44.39-0.72
-1.60%
Zevenbergen Growth Institutional

MNPR and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNPR has been loosely correlated with QNCX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if MNPR jumps, then QNCX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNPR
1D Price
Change %
MNPR100%
+6.30%
QNCX - MNPR
34%
Loosely correlated
-0.62%
RAPT - MNPR
26%
Poorly correlated
+4.12%
NEUP - MNPR
25%
Poorly correlated
+11.97%
AGIO - MNPR
25%
Poorly correlated
-0.84%
ZLAB - MNPR
25%
Poorly correlated
-3.26%
More

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ONC. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ONC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
-3.26%
ONC - ZLAB
56%
Loosely correlated
-2.59%
CGEM - ZLAB
38%
Loosely correlated
-3.03%
BMRN - ZLAB
37%
Loosely correlated
-0.98%
ZYME - ZLAB
36%
Loosely correlated
-1.03%
IRON - ZLAB
36%
Loosely correlated
+1.08%
More